Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV. When she’s not chasing stories, she enjoys reading and exploring new places.
Latest from Sushmita Panda
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.